Methods and compositions for protection of cells and tissues from computed tomography radiation
Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and in cells affected by computed tomography (CT) radiation. Subjects receiving ionizing radiation may be those persons suspected of having cancer, or cancer patients having received or currently receiving cancer therapy, and or those patients having received previous ionizing radiation, including those who are approaching or have exceeded the recommended total radiation dose for a person.
1. A method of inhibiting genomic instability in a subject caused by computed tomography (CT) scan radiation comprising administering to the subject an effective dose of a phosphorothioate compound or derivative thereof prior to and/or following exposure to the CT scan radiation wherein the phosphorothioate compound or derivative thereof is selected from amifostine, WR-1065, WR-638, WR-3689, WR-2822, WR-2529, WR-77913, WR-255591, WR-2823, WR-33278, WR-255709, WR-151326, and WR-151327; wherein:
the radiation dose is 1-25 cGy; and
inhibiting genomic instability is selected from reducing micronuclei formation, reducing γ-H2AX formation, reducing chromosome translocation frequency, reducing HPRT mutant frequency, and reducing hyper-recombination.
2. The method of claim 1 , wherein the phosphorothioate or derivative thereof is administered prior to exposure to the CT scan radiation.
3. The method of claim 1 , wherein the phosphorothioate or derivative thereof is administered up to one hour following exposure to the CT scan radiation.
4. The method of claim 1 , wherein the phosphorothioate or derivative thereof is administered prior and within 30 minutes after exposure to the CT scan radiation.
5. The method of claim 1 , wherein the phosphorothioate or derivative thereof is amifostine or WR1065.
6. The method of claim 1 , wherein the phosphorothioate or derivative thereof is administered subcutaneously, intravenously, topically, transdermally, orally, or using an auto-injector device.
7. The method of claim 1 , wherein the subject has been diagnosed with cancer or is suspected of having cancer.
8. The method of claim 1 , wherein the subject has had 1, 2 or 3 previous CT scans.
9. The method of claim 1 , wherein the subject is a human or non-human animal.
10. The method of claim 1 , wherein the antioxidant is selected from resveratrol, vitamin E, selenium, and catalase.
11. The method of claim 1 , wherein the effective dose of a phosphorothioate compound or derivative thereof is administered prior to and/or up to 1, 2, or 3 hours following exposure to the CT scan radiation.
12. The method of claim 11 , wherein further comprising diagnosing cancer in the subject using the computed tomography (CT) scan and/or treating the subject with cytoprotection.
13. A method of inhibiting genomic instability in a subject caused by diagnostic radiology procedures that involve exposure to ionizing radiation, comprising administering to the subject an effective dose of a phosphorothioate compound or derivative thereof prior to and/or following exposure to the diagnostic radiology procedure wherein the phosphorothioate compound or derivative thereof is selected from amifostine, WR-1065, WR-638, WR-3689, WR-2822, WR-2529, WR-77913, WR-255591, WR-2823, WR-33278, WR-255709, WR-151326, and WR-151327, wherein:
the radiation dose is 1-25 cGy;
inhibiting genomic instability is selected from reducing micronuclei formation, reducing γ-H2AX formation, reducing chromosome translocation frequency, reducing HPRT mutant frequency, and reducing hyper-recombination; and
the diagnostic radiology procedure is selected from x-ray and computed tomography (CT).
14. The method of claim 2 , wherein the phosphorothioate or derivative thereof is administered within 5 hours prior to exposure to the CT scan radiation.
15. The method of claim 1 , wherein the genomic instability occurs within a 24-hour period after administration of the compound.
16. The method of claim 2 , wherein the phosphorothioate or derivative thereof is administered at least 3 hours prior to exposure to the CT scan radiation.
17. The method of claim 1 , wherein the CT scan radiation comprises ionizing radiation.
18. The method of claim 1 , further comprising administering to the subject an antioxidant.
19. The method of claim 13 , further comprising administering to the subject an antioxidant.